Titles
- Equilibrium effects of pharmaceutical bundling: evidence from India1
- Estimated changes to employer-sponsored health insurance premiums due to the drug inflation rebate provision of the Build Back Better Act1
- Examining two approaches to U.S. drug pricing: international prices and therapeutic equivalency1
- Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries1
- Fact sheet. The 340B Drug Pricing Program1
- Getting to lower prescription drug prices: the key drivers of costs and what policymakers can do to address them1
- Getting to the root of high prescription drug prices: drivers and potential solutions1
- High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia1
- How Medicaid and CHIP shield children from the rising costs of prescription drugs1
- How does the Trump Administration drug pricing blueprint affect Medicaid?1
- How prescription drug use affects health care utilization and spending by older Americans: a review of the literature1
- How state Medicaid programs are managing prescription drug costs: results from a state Medicaid pharmacy survey for state fiscal years 2019 and 20201
- How to strengthen the Medicaid Drug Rebate Program to address rising Medicaid prescription drug costs1
- How will the Medicare Part D benefit change under current law and leading proposals?1
- Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit1
- Insurance market reform: 1
- MAT for hospitalized patients1
- Making drug costs more transparent to consumers: a summary for policymakers1
- Management of patients with opioid dependence: a review of clinical, delivery system, and policy options1
- Manufacturers may need additional guidance to ensure consistent calculations of average sales prices1